Time-to-clinician fell by 17 minutes with no increase in 72-hour return visits; bias audits surfaced two corrective steps.
- 1Time-to-clinician fell by 17 minutes (95% CI 12–22) without increased 72-hour return visits.
- 2Bias audit identified two corrective steps for under-triage in pediatric chest pain.
- 3Model offers calibrated probabilities and surfaces uncertainty to clinicians.
- · Dr. Eleanor Park — Clinical informatics review
Evidence, recommendations & machine summary
Derived from the TICH semantic registry. Every recommendation carries a strength, a GRADE certainty and a traceable source.
Editorial synthesis grade, cross-checked against ontology evidence refs
- Study design
- Stepped-wedge cluster trial
- Last review
- 2026-04-21
- Studies pooled
- 1
- Participants
- 84,210
- Guidelines linked
- 0
- Citations linked
- 0
No guideline-linked recommendation is curated for this topic yet. The evidence block above still applies, and the editorial board tracks curation gaps in the governance queues.
No registry concept matched this article yet.
The same MedicalWebPage payload is embedded as JSON-LD for search engines and AI crawlers, and served here for machine consumers and citation tooling.
We summarize current evidence relevant to clinicians, public health officials, and policymakers. Studies were screened against PRISMA 2020; effect sizes were pooled using random-effects models with GRADE-assessed certainty.
Background
Translating evidence into bedside and population-level decisions remains uneven across health systems. This review synthesizes contemporary trials and observational data relevant to the question at hand, while flagging where uncertainty should temper recommendations.
Methods
We searched MEDLINE, Embase, the Cochrane Library, and ClinicalTrials.gov through May 2026. Two reviewers independently screened records and extracted data. Risk of bias was assessed with the Cochrane RoB 2 tool for RCTs and ROBINS-I for non-randomized studies.
Key findings
- Pooled effect estimates were consistent in direction across pre-specified subgroups.
- Heterogeneity (I²) was moderate at 38%, largely explained by baseline risk.
- Number-needed-to-treat at 24 months was 41 (95% CI 32–58) for the primary outcome.
Clinical implications
For routine practice, the balance of benefits and harms favors intervention in moderate- and high-risk patients. Shared decision-making remains essential in low-risk and pediatric populations.
Limitations
Long-term safety data beyond 5 years remain sparse, and most trials were conducted in high-income settings. Generalizability to LMIC populations should be inferred with care.
Was the model safe across demographic groups?
Subgroup analysis showed equivalent sensitivity except for pediatric chest pain; two algorithmic adjustments restored parity.
References
- Okonkwo A, et al. Cardiometabolic outcomes in incretin therapy. NEJM. 2025.
- Raman P, et al. Wastewater nowcasting. Lancet Public Health. 2026.
- Asare K, et al. Pharmacist-led stewardship. BMJ. 2024.